Answers are grounded in this paper and cite their sources.
AQST-109 delivered epinephrine with PK and PD results within the bracketed range of approved intramuscular products. AQST-109 has promise as an innovative, needle-free, nondevice, portable, and orally delivered alternative for first-line treatment of type I allergic reactions, including anaphylaxis.
No takes yet. Share an insight, caveat, or question.
Kraus et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: